💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Geron Corporation (GERN)
« Back to company indexGERN Chatter Timeline
Stock Ticker for GERN
Most Active Tweeters for GERN
| User | Tweets |
|---|---|
| @OmarPridelands | 35 |
| @1000Shares | 7 |
| @Gambiste1 | 6 |
| @MarcJacksonLA | 3 |
| @OilStocker | 2 |
Recent Tweets for GERN
 |
@OmarPridelands $gern check out imetelchat https://t.co/PFRgJ25q4D April 19th 2021, 9:04pm |
 |
@ChartMill A Quick Ratio of 6.46 indicates that $GERN has no problem at all paying its short term obligations.… https://t.co/q4eIH7pR4o April 19th 2021, 2:04am |
 |
@FlashAlert_me $GERN [15s. delayed]: Issued Press Release on April 18, 08:00:00: Lifshitz Law Firm, P.C. Announces Investigations… https://t.co/3v7mN3sa6L April 18th 2021, 12:04pm |
|
@OmarPridelands $gern https://t.co/0m8MvcJZaB April 17th 2021, 3:04am |
|
@OmarPridelands RT @TMAN1138pm: $GERN #Bloodcancer #Imetelstat April 16th 2021, 7:04pm |
 |
@TMAN1138pm $GERN #Bloodcancer #Imetelstat https://t.co/Z6aA0Vx4Qk April 16th 2021, 5:04pm |
 |
@MarcJacksonLA $GERN Phase 3 Study of Imtelstat Versus BAT Explores Survival Improvement in Myelofibrosis https://t.co/FRI1DA2WuL via @targetedonc April 15th 2021, 8:04pm |
|
@OmarPridelands RT @hadidy_sara: $GERN: Signals could not be any clearer on the 1-minute chart of GERN. Awaiting Buy Signal https://t.co/uLmwgJaeyx April 15th 2021, 2:04pm |
 |
@hadidy_sara $GERN: Signals could not be any clearer on the 1-minute chart of GERN. Awaiting Buy Signal https://t.co/uLmwgJaeyx April 15th 2021, 9:04am |
|
@OmarPridelands RT @newsfilterio: Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis $GERN https://t.co/mV4… April 14th 2021, 2:04pm |
|
@OmarPridelands RT @1stOncology: #Geron Announces First Patient Dosed in #IMpactMF Phase 3 Clinical Trial in #Refractory #Myelofibrosis $GERN https://t.co/… April 14th 2021, 2:04pm |
 |
@1stOncology #Geron Announces First Patient Dosed in #IMpactMF Phase 3 Clinical Trial in #Refractory #Myelofibrosis $GERN https://t.co/wEv1bVVfEh April 14th 2021, 10:04am |
 |
@newsfilterio Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis $GERN https://t.co/mV4QLJWFDC April 14th 2021, 7:04am |
|
@newsfilterio Geron starts dosing in late-stage blood cancer study $GERN https://t.co/s8i4CHbCnU April 14th 2021, 7:04am |
|
@OmarPridelands @StockLizardKing $gern April 13th 2021, 11:04pm |
|
@OmarPridelands RT @SmallCapsDaily: $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis Business Wire… April 13th 2021, 6:04pm |
|
@OmarPridelands RT @equity_newswire: $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis https://t.co/… April 13th 2021, 6:04pm |
|
@OmarPridelands RT @HillScottW: $GERN Yuge drop in short interest and now this? nothing has changed. nice lotto https://t.co/p8wuxVWvbo April 13th 2021, 6:04pm |
 |
@HillScottW $GERN Yuge drop in short interest and now this? nothing has changed. nice lotto https://t.co/p8wuxVWvbo April 13th 2021, 6:04pm |
 |
@equity_newswire $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis https://t.co/C7E3XS3886 April 13th 2021, 5:04pm |
 |
@SmallCapsDaily $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis Business W… https://t.co/bHVUBIPLp9 April 13th 2021, 3:04pm |
|
@OmarPridelands RT @stock_titan: $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis https://t.co/DQ49… April 13th 2021, 2:04pm |
|
@OmarPridelands RT @TeamofStockTra: $GERN - Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis April 13th 2021, 2:04pm |
|
@OmarPridelands RT @AkramMSiddique: $GERN - Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis April 13th 2021, 2:04pm |
|
@OmarPridelands RT @FlashAlert_me: $GERN [15s. delayed]: Issued Press Release on April 13, 07:30:00: Geron Announces First Patient Dosed in IMpactMF Phase… April 13th 2021, 2:04pm |
|
@OmarPridelands RT @sbwcws: Geron announces first patient dosed in IMpactMF trial $GERN April 13th 2021, 2:04pm |
|
@OmarPridelands RT @CHItraders: $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis | Business Wire ht… April 13th 2021, 2:04pm |
|
@OmarPridelands RT @Beeken_health: $GERN - Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis https://t.co/… April 13th 2021, 2:04pm |
|
@OmarPridelands RT @MarketCurrents: $GERN - Geron starts dosing in late-stage blood cancer study https://t.co/LEA3m8hrcf April 13th 2021, 2:04pm |
|
@OmarPridelands RT @moneymessage_: $GERN - Geron starts dosing in late-stage blood cancer study https://t.co/nFMKyDfJJc April 13th 2021, 2:04pm |
|
@MarcJacksonLA $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis | Business… https://t.co/vF92MjLyT9 April 13th 2021, 2:04pm |
 |
@moneymessage_ $GERN - Geron starts dosing in late-stage blood cancer study https://t.co/nFMKyDfJJc April 13th 2021, 1:04pm |
 |
@OilStocker $GERN @ $1.42 2021-04-13 @ 8:15 AM EST Geron Doses First Patient in Phase 3 Study of Potential Blood Cancer Drug I… https://t.co/ps18RNXskp April 13th 2021, 12:04pm |
|
@OilStocker $GERN @ $1.42 2021-04-13 @ 7:30 AM EST Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis April 13th 2021, 12:04pm |
 |
@MarketCurrents $GERN - Geron starts dosing in late-stage blood cancer study https://t.co/LEA3m8hrcf April 13th 2021, 11:04am |
 |
@Beeken_health $GERN - Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis… https://t.co/ecNqqT9Hmc April 13th 2021, 11:04am |
 |
@CHItraders $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis | Business… https://t.co/frdz7xFh9y April 13th 2021, 11:04am |
 |
@sbwcws Geron announces first patient dosed in IMpactMF trial $GERN April 13th 2021, 11:04am |
|
@FlashAlert_me $GERN [15s. delayed]: Issued Press Release on April 13, 07:30:00: Geron Announces First Patient Dosed in IMpactMF P… https://t.co/iFqNIv5jJ7 April 13th 2021, 11:04am |
 |
@AkramMSiddique $GERN - Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis April 13th 2021, 11:04am |
 |
@stock_titan $GERN Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis… https://t.co/EDG9B4lEk5 April 13th 2021, 11:04am |
 |
@Gambiste1 RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 2 of 8 $GERN https://t.co/e8NHrjpHUr April 10th 2021, 6:04pm |
|
@Gambiste1 RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 1 of 8 $GERN https://t.co/jlIrSVwoDq April 10th 2021, 6:04pm |
|
@Gambiste1 RT @_sdrawkcabeman_: A note on Imerge, Part1/3. $GERN 7/13(54%) TI in original. PREMATURE expansion data was 7/25(28%); but mean burden=6… April 10th 2021, 6:04pm |
|
@Gambiste1 RT @_sdrawkcabeman_: A note on Imerge, Part2/3. $GERN HI-E =71% w/68% reduction! +today's data says mTI not yet reached, data STILL DEVELO… April 10th 2021, 6:04pm |
|
@Gambiste1 RT @_sdrawkcabeman_: A note on Imerge, Part3/3. $GERN Incredible DEPTH of response gives me sufficient reason to blve more pts w/mean 2 ex… April 10th 2021, 6:04pm |
|
@OmarPridelands RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 3 of 8 $GERN https://t.co/HEYi7Uc1fT April 10th 2021, 6:04pm |
|
@OmarPridelands RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 4 of 8 $GERN https://t.co/QdeTG5U2Ia April 10th 2021, 6:04pm |
|
@OmarPridelands RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 5 of 8 $GERN https://t.co/4kAkEbZE2Q April 10th 2021, 6:04pm |
|
@OmarPridelands RT @_sdrawkcabeman_: The Dec 10th ASH 2018 CC Part 6 of 8 $GERN https://t.co/yzy7QFx9DU April 10th 2021, 6:04pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
